Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMA grants orphan designation to selumetinib to treat neurofibromatosis type 1
Image: AstraZeneca and Merck have secured European orphan designation for selumetinib to treat neurofibromatosis type 1. Photo: courtesy of AstraZeneca.
Image: AstraZeneca and Merck have secured European orphan designation for selumetinib to treat neurofibromatosis type 1. Photo: courtesy of AstraZeneca.